Hydrochlorothiazide
Hydrochlorothiazide
CAS: 58-93-5
Molecular Formula: C7H8ClN3O4S2
Hydrochlorothiazide - Names and Identifiers
| Name | Hydrochlorothiazide |
| Synonyms | 200-403-3 Hydrochlorothiazide 6-chloro-7-sulfamoyl-3,4-dihydro-2h-1,2,4-benzothiadiazine 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide 3,4-Dihydro-6-chloro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide 6-Chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide 6-Chloro-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide 6-Chloro-3,4-dihydro-7-sulphamoyl-1,2,4-ben-zoth-iadi-azine1,1-dioxcide 2h-1,2,4-benzothiadiazine-7-sulfonamide,6-chloro-3,4-dihydro-,1,1-dioxide 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide |
| CAS | 58-93-5 |
| EINECS | 200-403-3 |
| InChI | InChI=1/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10H,3H2,(H3-,9,11,12,13,14,15) |
| InChIKey | JZUFKLXOESDKRF-UHFFFAOYSA-N |
Hydrochlorothiazide - Physico-chemical Properties
| Molecular Formula | C7H8ClN3O4S2 |
| Molar Mass | 297.74 |
| Density | 1.6761 (rough estimate) |
| Melting Point | 273 °C |
| Boling Point | 577.0±60.0 °C(Predicted) |
| Flash Point | 9℃ |
| Water Solubility | 722mg/L(25 ºC) |
| Solubility | Very slightly soluble in water, soluble in acetone, sparingly soluble in ethanol (96 per cent). It dissolves in dilute solutions of alkali hydroxides |
| Appearance | solid |
| Color | White to Off-White |
| Maximum wavelength(λmax) | ['318nm(H2O)(lit.)'] |
| Merck | 14,4781 |
| BRN | 625101 |
| pKa | 7.9, 9.2(at 25℃) |
| Storage Condition | 2-8°C |
| Stability | Stable. Incompatible with strong oxidizing agents. |
| Refractive Index | 1.6100 (estimate) |
| Physical and Chemical Properties | Melting Point: 274 water-soluble:<0.01g/100 mL at 22.5 C
|
| Use | Diuretics |
Hydrochlorothiazide - Risk and Safety
| Risk Codes | R22 - Harmful if swallowed R42/43 - May cause sensitization by inhalation and skin contact. R36/38 - Irritating to eyes and skin. R23/25 - Toxic by inhalation and if swallowed. R36/37/38 - Irritating to eyes, respiratory system and skin. R39/23/24/25 - R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. R11 - Highly Flammable |
| Safety Description | S22 - Do not breathe dust. S24 - Avoid contact with skin. S36/37 - Wear suitable protective clothing and gloves. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S33 - Take precautionary measures against static discharges. S16 - Keep away from sources of ignition. S7 - Keep container tightly closed. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S27 - Take off immediately all contaminated clothing. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
| UN IDs | UN 1230 3/PG 2 |
| WGK Germany | 2 |
| RTECS | DK9100000 |
| TSCA | Yes |
| HS Code | 29350090 |
| Hazard Note | Irritant |
| Toxicity | LD50 in mice (mg/kg): 590 i.v.; >8000 orally (Piala) |
Hydrochlorothiazide - Standard
Authoritative Data Verified Data
This product is 6-chloro-3, 4-dihydro-2h-1, 2, 4-benzothiadiazine-7-sulfonamide -1, 1-dioxide. The content of C7H8C1N304S2 shall be 98.0% ~ 102.0% calculated as the dry product.
Last Update：2024-01-02 23:10:35
Hydrochlorothiazide - Trait
Authoritative Data Verified Data
- This product is white crystalline powder; Odorless.
- This product is dissolved in acetone, slightly soluble in ethanol, insoluble in water, chloroform or ether; Dissolved in sodium hydroxide solution.
Last Update：2022-01-01 13:42:02
Hydrochlorothiazide - Differential diagnosis
Authoritative Data Verified Data
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- take 50mg of this product, put it in a 100ml measuring flask, add 0. Dissolve 10ml of 1mol/L sodium hydroxide solution, dilute to scale with water, shake well, take 2ml with precision, put it in a ml measuring flask, dilute to scale with 0.01mol/L sodium hydroxide solution, shake, according to UV-visible spectrophotometry (General 0401), there is maximum absorption at 273nm and 323nm wavelength, the ratio of the absorbance at a wavelength of 273nm to the absorbance at a wavelength of 323nm is 5.4 to 5.7.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 285).
Last Update：2022-01-01 13:42:04
Hydrochlorothiazide - Exam
Authoritative Data Verified Data
pH
take 0.50g of this product, add 25ml of water, shake for 2 minutes, filter, take 10ml of filtrate, add 0.Olmol/L sodium hydroxide solution 0.2ml and methyl red indicator solution 0.15, the solution should be yellow. Add 0.4ml of 0.Olmol/L hydrochloric acid solution, the solution should be red.
chloride
take this product l.Og, add water 20ml, shake, filter, separate filtrate 10ml, check according to law (General rule 0801), compared with the control solution made of standard sodium chloride solution 5.0ml, not more concentrated (O.Ol%).
Related substances
take about 15mg of this product, add organic phase [methanol-acetonitrile (1:1)]2.5ml dissolved, dilute the water phase [0.02mol/L potassium dihydrogen phosphate solution (adjust pH to 3.2 with phosphoric acid)] to 10ml, shake well, as a test solution; Take appropriate amount with precision, A mixed solvent [organic phase-aqueous phase (1:3 ) ] was added for quantitative dilution to prepare a solution containing 7.5% per 1 ml as a control solution. According to the high performance liquid chromatography (General 0512) test, using eighteen alkyl silane bonded silica gel as filler, with water phase-methanol-tetrahydrofuran (94:6:1) as mobile phase A, an aqueous phase-methanol-tetrahydrofuran (50:50:5) was used as mobile phase B; The flow rate was 1.0mL per minute, and gradient elution was performed according to the following table; The detection wavelength was 224nm. Take about 15mg of hydrochlorothiazide and about 15mg of chlorothiazide respectively, put them in the same volume of 100ml, dissolve them in 25ml of organic phase, dilute them to scale with water, shake well, take appropriate amount, the mixed solvent is added to dilute to prepare a solution containing about 7.5ug in each lml. As the system applicable solution, l0ul is injected into the liquid chromatograph. The separation degree of hydrogen thiazide peak and chlorothiazide peak should be greater than 2.5. The sample solution and the control solution are respectively injected into the liquid chromatograph to record the chromatogram. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than the area of the main peak of the control solution (0.5% ) , and the sum of each impurity peak area shall not be greater than 2 times the area of the main peak of the control solution (1.0%). The peaks in the chromatogram of the test solution which are 0.1 times (0.05%) smaller than the main peak area of the control solution are ignored.
residual solvent
take about 0.25g of this product, weigh it accurately, put it in a 20ml headspace bottle, add 2ml of N,N-dimethylformamide, shake it to dissolve it, precision Plus internal standard solution (take the appropriate amount of isopropanol, diluted with water to make a solution containing about 0.2mg per 1ml) 1ml, diluted with water to 10ml, sealed, shake, as a test solution. Weigh methanol and ethanol respectively, accurately weigh and dilute with water to make solutions containing about 0.15mg and 0.25mg of methanol and ethanol respectively per 1 ml. Take 5ml of precision, put into 20ml of headspace bottle, add 2ml of N,N-dimethylformamide, 1ml of precision plus internal standard solution, dilute to 10ml with water, seal, as a reference solution. According to the test for determination of residual solvents (General rule 0861, second method), 6% cyanopropyl-94% methylpolysiloxane (or polar similar) is used as the stationary liquid; The initial temperature is 40°C, and after 8 minutes, the temperature was increased to 200°C at a rate of 45°C per minute for 3 minutes. The inlet temperature was 200°C; The detector temperature was 250°C; The equilibrium temperature of the headspace bottle was 80°C, and the equilibrium time was 30 minutes, the separation degree of methanol peak and ethanol peak should meet the requirements. Then the reference solution and the test solution were injected into the headspace, and the chromatogram was recorded. According to the internal standard method, the residual amount of methanol and ethanol should be calculated by the ratio of peak area.
loss on drying
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
ignition residue
not more than 0.1% (General rule 0841).
Heavy metals
take this product 1.Og, add sodium hydroxide test solution 7ml dissolved, diluted with water to 25ml, inspection according to law (General rule 0821 third method), containing heavy metals shall not exceed 15 parts per million.
Last Update：2022-01-01 13:42:06
Hydrochlorothiazide - Content determination
Authoritative Data Verified Data
measured by high performance liquid chromatography (General 0512).
chromatographic conditions and system suitability test
silica gel bonded with eighteen alkyl silane as a filler; 0.1 mol/L sodium dihydrogen phosphate-acetonitrile (9:1)(adjusted to pH 3.0±0.1 with phosphoric acid) was used as mobile phase; The detection wavelength was 271nm; The flow rate was 1.5ml per minute; The column temperature was 30°C. Hydrochlorothiazide and chlorothiazide control were taken, dissolved and diluted with mobile phase to prepare solutions containing 0.05mg each per 1 ml, which were tested as system-suitable solutions. Hydrochlorothiazide and chlorothiazide peak separation should be greater than 2.0.
assay
take about 20mg of this product, weigh it accurately, put it in a 100ml measuring flask, add 5ml of methanol-acetonitrile (1:l), shake it to dissolve it, dilute it to scale with mobile phase, shake well, take an appropriate amount with precision, and quantitatively dilute with mobile phase to make a solution containing about 50ug per lml, which is used as a test solution. Take 10u1 injection into human liquid chromatograph with precision, and record the chromatogram; another hydrochlorothiazide reference substance was determined by the same method. According to the external standard method to calculate the peak area, that is.
Last Update：2022-01-01 13:42:07
Hydrochlorothiazide - Category
Authoritative Data Verified Data
diuretics, antihypertensive drugs.
Last Update：2022-01-01 13:42:08
Hydrochlorothiazide - Storage
Authoritative Data Verified Data
light shielding, sealed storage.
Last Update：2022-01-01 13:42:09
Hydrochlorothiazide - Hydrochlorothiazide Tablets
Authoritative Data Verified Data
This product contains hydrochlorothiazide (C7H8C1N304S2) should be the label amount of 93.0% ~ 107.0%.
trait
This product is white tablet.
identification
take an appropriate amount of the fine powder of this product (about 10mg equivalent to hydrochlorothiazide), add 10ml of acetone to shake and dissolve hydrochlorothiazide, filter, and take the continued filtrate as the test solution; another hydrochlorothiazide control was taken, dissolved in acetone and diluted to make a 0.1% solution as a control solution. Take 5 u1 of each of the above two solutions, respectively, on the same silica gel GF 254 thin layer plate, with ethyl acetate as the developing solvent, spread out, dry, put under UV light (254nm) to view, the position and color of the spots displayed by the test solution should be the same as the main spot of the control solution.
examination
- Related Substances: take an appropriate amount of the fine powder of this product (equivalent to about 15mg of hydrochlorothiazide) and add 2.5ml of organic phase [methanol-acetonitrile (1:1)] to dissolve hydrochlorothiazide, dilute the aqueous phase [0.02mol/L potassium dihydrogen phosphate solution (adjust pH to 3.2 with phosphoric acid)] to 10ml, shake well, filter, and take the continued filtrate as the test solution, the determination was carried out according to the method for related substances of hydrochlorothiazide. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be more than 2 times (1.0%) the area of the main peak of the control solution, the sum of each impurity peak area shall not be greater than 4 times (2.0%) of the main peak area of the control solution. The peaks in the chromatogram of the test solution which are 0.1 times (0.05%) smaller than the main peak area of the control solution are ignored.
- Content uniformity take 1 tablet of this product, put it in a 200ml measuring flask (lOmg specification) or a 500ml measuring flask (25mg specification), add 10ml of mobile phase, and place it for 30 minutes, add methanol-acetonitrile (1:l)10ml, ultrasonic treatment to dissolve hydrochlorothiazide, let it cool, dilute to the scale with mobile phase, shake, filter, take the continued filtrate as the test solution, and determine the content according to the method under the content determination item, which shall comply with the regulations (General rule 0941).
- dissolution of this product, according to the dissolution and release determination method (General 0931 first method), with 0.100 ml of 1 mol/L hydrochloric acid solution is the dissolution medium, and the rotation speed is rpm, and the operation is carried out according to law. After 30 minutes, 10ml of the solution is taken, filtered, and the appropriate amount of the filtrate is taken, quantitatively dilute with dissolution medium to prepare a solution containing about 5-10ug per 1 ml, and measure absorbance at the wavelength of 272nm according to ultraviolet-visible spectrophotometry (General rule 0401); another hydrogen thiazide reference substance was accurately weighed, dissolved and quantitatively diluted with dissolution medium to make a solution containing about 5-10ug per 1 ml, and the dissolution amount of each tablet was calculated by the same method. The limit is 60% of the labeled amount and shall be in accordance with the provisions.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
Take 20 tablets of this product, precision weighing, fine grinding, precision weighing fine powder appropriate amount (equivalent to about hydrochlorothiazide 20mg), 100ml flask, add methanol-acetonitrile (1:l)5ml, shake, add mobile phase 20ml, ultrasonic about 5 minutes to dissolve hydrochlorothiazide, let it cool, dilute to scale with mobile phase, shake well, filter, take appropriate amount of filtrate with precision, A solution containing about 50ug per 1 ml was prepared by dilution with the mobile phase, and as a test solution, it was measured according to the method under the item of hydrochlorothiazide content measurement. According to the external standard method to calculate the peak area, that is.
category
Same as hydrochlorothiazide.
specification
(l)10mg (2)25mg (3)50mg
storage
light shielding, sealed storage.
Last Update：2022-01-01 13:42:10
Hydrochlorothiazide - Reference Information
| NIST chemical information | Information provided by: webbook.nist.gov (external link) |
| (IARC) carcinogen classification | 2B (Vol. 50, 108) 2016 |
| EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
| Overview | Hydrochlorothiazide, also known as dihydrochlorothiazide and dihydrochlorothiazide, is a thiazide diuretic with moderate diuretic effect. By acting on the cortical part of the ascending branch of the medulla, the active reabsorption of Cl-and the passive absorption of Na in this part are inhibited, thereby diuresis. In addition, this product also has antihypertensive and antidiuretic effects. Suitable for all kinds of edema, especially cardiogenic edema. It can also be used as an antihypertensive drug for the treatment of mild and medium-sized hypertension. It also has a certain effect on diabetes insipidus and idiopathic hypercalciuria. Commonly used thiazide diuretics include hydrochlorothiazide, chlorthalidone, indapamide, etc. |
| pharmacological action | (1) sodium excretion and diuresis: this product mainly inhibits the reabsorption of Na + and Cl-by the anterior and proximal tubules of the distal tubules (less effective), increases the plasma excretion of sodium, potassium, chlorine, phosphorus and magnesium in urine, and reduces the excretion of calcium in urine. (2) Antihypertensive effect: It has a mild and definite antihypertensive effect. The systolic and diastolic blood pressure in the opposite position and decubitus position can be reduced, and the antihypertensive effect of other antihypertensive drugs can also be increased. (3) Antidiuretic effect: This product can reduce the urine volume of nephrogenic diabetes insipidus, sometimes up to 50%, the specific mechanism of action is unknown. Fig. 2 shows hydrochlorothiazide tablets |
| pharmacokinetics | oral absorption is rapid but incomplete. eating can increase absorption, which may be related to the prolonged retention time of drugs in the small intestine. Part of this product binds to plasma proteins, and the other part enters red blood cells. After 2h of oral administration, the peak time is 4h, and the duration of action is 6~12h. The main form is excreted with urine, the half-life (t1/2) is 15h, and the t1/2 of patients with renal insufficiency is prolonged. |
| Indications | Hydrochlorothiazide (HCTZ, HCT or HZT for short) is currently the most commonly used oral thiazide diuretic in clinical practice. It is usually used to treat hypertension and edema caused by fluid accumulation. Other uses include the treatment of diabetes insipidus and renal tubular acidosis, which can also reduce hypercalciuria, thereby reducing the risk of kidney stones. In addition, this drug is often used as the first-line drug for the treatment of hypertension. Hydrochlorothiazide is an oral drug, sometimes mixed with other antihypertensive drugs to make compound tablets to enhance the efficacy. (1) Edematous diseases: including congestive heart failure, liver cirrhosis ascites, nephrotic syndrome, acute and chronic nephritis edema, early chronic renal failure, sodium and water retention caused by adrenal cortex hormone and estrogen therapy. (2) Hypertension: It can be used alone or in combination with other antihypertensive drugs, mainly for the treatment of essential hypertension. (3) Central or renal diabetes insipidus. (4) Nephrolithiasis: It is mainly used to prevent stones formed by calcium salts. |
| usage and dosage | oral normal release dosage form: oral administration takes effect for 2 hours, blood drug concentration peaks for 4 hours, and the effect lasts for 6~12 hours. Adults:(1) treat edema disease, once 25~50mg,qd or bid, or qod; Or take medicine for 3~5 days every week, intermittent for 3~4 days. (2) Treatment of hypertension, 25~100mg a day, divided into 1~2 times, need to be combined with other antihypertensive drugs, and adjust the dose according to the antihypertensive effect, usually reduced to 25~50mg a day after 1 week. (3) Treatment of diabetes insipidus, once 25mg,tid, or once 50mg,qd. Children: For the treatment of edema diseases, 1~2 mg/kg per day, 1~2 times, and adjust the dose according to the curative effect. |
| adverse reactions | most adverse reactions are related to dosage and course of treatment. (1) Adverse reactions caused by water and electrolyte disorders are more common: hypokalemia is more likely to occur, which is related to the potassium excretion effect of thiazide diuretics. Long-term potassium deficiency can damage the renal tubules, and severe potassium loss can cause The vacuolar changes of the renal tubular epithelium and the ectopic heart rhythm such as severe tachyarrhythmia. Thiazides, especially hydrochlorothiazide, often significantly increase the excretion of chloride, causing low-chlorine alkalosis or low-chlorine and low-potassium alkalosis. In addition, hyponatremia is not uncommon, leading to central nervous system symptoms and aggravating renal damage. Dehydration causes a decrease in blood volume and renal blood flow, which can also cause a decrease in glomerular filtration rate. The common clinical manifestations of water and electrolyte disorders include dry mouth, polydipsia, muscle cramps, nausea, vomiting, and extreme fatigue. (2) Hyperglycemia: This product can reduce glucose tolerance and increase blood sugar, which may be related to inhibiting insulin release. (3) Hyperuricemia: Interfering with the excretion of uric acid in renal tubules, a few can induce gout attacks. There is usually no joint pain, so hyperuricemia is easily ignored. (4) Allergy: such as rash, urticaria, etc., are relatively rare. (5) Leukopenia or deficiency, thrombocytopenic purpura, etc. are also rare. (6) Rare cholecystitis, pancreatitis, sexual dysfunction, light sensitivity, color vision disorder, etc. |
| precautions | (1) cross allergy: cross allergy with sulfa drugs, furosemide, bumetanide and carbonic anhydrase inhibitors. (2) Use with caution in the following situations: ①For those with anuria or severe renal dysfunction, due to the poor effect of this type of drug, the drug accumulation and increased toxicity can be caused when large doses are applied; ②Diabetes; ③Hyperuricemia or Gout history; ④For severe liver damage, water and electrolyte disorders can induce hepatic encephalopathy; ⑤ Hypercalcemia; ⑥ Hyponatremia; ⑦ Lupus erythematosus, which can aggravate the condition or induce activity; ⑧ Pancreatitis; ⑨ Sympathetic nerve resection (enhanced antihypertensive effect);⑩ Infants with jaundice. (3) Can pass through the blood-placental barrier, pregnant women should be careful to use. It should not be taken by lactating women. (4) Elderly patients are more prone to hypotension, electrolyte disturbance and renal damage when using this class of drugs. (5) The medication should be started from the minimum effective amount to reduce adverse reactions and reduce the secretion of reflex renin and aldosterone. (6) Patients with hypokalemia tendency should be supplemented with potassium or combined with potassium-sparing diuretics as appropriate. (7) Follow-up examination: ① blood electrolyte; ② blood sugar; ③ blood uric acid; ④ blood creatinine; ⑤ blood urea nitrogen; ⑥ blood pressure. (8) Interference with diagnosis: can cause impaired glucose tolerance, blood sugar, urine sugar, blood bilirubin, blood calcium, blood uric acid, blood cholesterol, triacylglycerol, low-density lipoprotein concentration, blood magnesium, potassium, Sodium and urine calcium decrease. (9) When overdose, gastric lavage should be given as soon as possible, support, symptomatic treatment, and close follow-up of blood pressure, electrolytes and renal function. (2015-11-17) |
| drug interaction | (1) adrenocortical hormone, corticotropin, estrogen, amphotericin B (intravenous medication) can reduce the diuretic effect of this product and increase the chance of electrolyte disturbance, especially hypokalemia. (2) Non-steroidal anti-inflammatory analgesics, especially indomethacin, can reduce the diuretic effect of this product, which is related to the former's inhibition of prostaglandin synthesis. (3) When combined with sympathomimetic amine drugs, the diuretic effect is weakened. (4) Coleenamine (cholestolamine) can reduce the absorption of this product by gastrointestinal tract, so this product should be taken 1 hour before or 4 hours after oral administration of the former. (5) Combined with dopamine, the diuretic effect is strengthened. (6) When combined with antihypertensive drugs, the diuretic antihypertensive effect is strengthened. (7) When combined with anti-gout drugs, the latter should adjust the dose. (8) The effect of anticoagulants is weakened, mainly due to the decrease of the body's plasma volume after diuresis, the level of blood coagulation factors increases, and diuresis improves the blood supply of the liver and increases the synthesis of coagulation factors. (9) Reduce the effect of hypoglycemic drugs. (10) Digitalis drugs, amiodarone, etc. are used in combination with this product, and should beware of adverse reactions caused by hypokalemia. (11) When combined with lithium preparations, this product can reduce the removal of lithium by the kidneys and increase the nephrotoxicity of lithium. (12) Urotropine is affected by this product, its conversion to formaldehyde is inhibited, and the curative effect is reduced. (13) Enhance the effect of non-depolarizing muscle relaxants, which is related to the decrease of blood potassium. (14) When combined with sodium bicarbonate, the chance of hypochlorinated alkalosis increases. |
| dosage form specification | hydrochlorothiazide tablets 10, 25, 50mg. |
| use | this product is a typical representative of thiazide medium-acting diuretics, ranking first in drug sales in the United States in 1985. Because it is convenient to take, the effect is medium, and it is suitable for various edema, so it is the most common clinical adverse reactions due to potassium excretion, and potassium salt needs to be supplemented when applied. The static and permanent injection LD50 of mice is 590mg/kg, and the oral LD50 is greater than 8000mg/kg. Diuretics It mainly inhibits the reabsorption of Na and Cl-by the proximal end of the distal curved tubule, and increases the excretion of sodium chloride by the kidney to produce diuresis. It is a medium-acting diuretic. This product has the effect of lowering blood pressure. It can be combined with Chinese medicines such as Li's medicine patch, antihypertensive application patch or apocynum. This product also has antidiuretic effect and can be used to treat diabetes insipidus a carbonic anhydrase inhibitor. |
| Production method | 5-chloro-2, 4-chlorosulfonylanilide is obtained from m-chloroaniline by chlorosulfonation, and 5-chloro-2, 4-chlorosulfonylaniline is formed by reammonia reaction, and finally prepared with formaldehyde. |
| category | toxic substances |
| toxicity classification | poisoning |
| acute toxicity | oral-rat LD50: 2750 mg/kg; Oral-mouse LD50: 1175 mg/kg |
| flammability hazard characteristics | flammability; fire scene decomposes toxic hydrogen chloride, sulfur oxides, nitrogen oxide gases |
| storage and transportation characteristics | warehouse low temperature, ventilation, drying |
| fire extinguishing agent | water, carbon dioxide, dry powder, sand |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-09 21:01:54
Supplier List
Spot supply
Product Name: Hydrochlorothiazide Visit Supplier Webpage Request for quotationCAS: 58-93-5
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Hydrochlorothiazide Request for quotation
CAS: 58-93-5
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 58-93-5
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Spot supply
Product Name: Hydrochlorothiazide Visit Supplier Webpage Request for quotationCAS: 58-93-5
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Hydrochlorothiazide Request for quotation
CAS: 58-93-5
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 58-93-5
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
View History